Sartorius Stedim Biotech (FR:DIM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Sartorius Stedim Biotech has released its first-half 2024 financial results and provides forecasts for the rest of the year. The internationally active biopharmaceutical partner reported a turnover of approximately 2.8 billion euros in 2023 and employs around 10,600 people globally. The full investor news is available on the company’s website.
For further insights into FR:DIM stock, check out TipRanks’ Stock Analysis page.